AUG 12, 2026 · PHASE 3 TRIAL
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 3 study with no results posted; it documents design and enrollment targets only.
Reported
Planned enrollment675
PhasePHASE3
Primary outcome measure 1Progression-Free Survival (PFS) in TROP2 bi…